206 related articles for article (PubMed ID: 36970721)
1. Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas.
Gao X; Kady N; Wang C; Abdelrahman S; Gann P; Sverdlov M; Wolfe A; Brown N; Reneau J; Robida AM; Murga-Zamalloa C; Wilcox RA
Cancer Res Commun; 2022 Dec; 2(12):1727-1737. PubMed ID: 36970721
[TBL] [Abstract][Full Text] [Related]
2. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.
Murga-Zamalloa C; Rolland DCM; Polk A; Wolfe A; Dewar H; Chowdhury P; Onder O; Dewar R; Brown NA; Bailey NG; Inamdar K; Lim MS; Elenitoba-Johnson KSJ; Wilcox RA
Clin Cancer Res; 2020 Feb; 26(3):690-703. PubMed ID: 31636099
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.
Cortes JR; Filip I; Albero R; Patiño-Galindo JA; Quinn SA; Lin WW; Laurent AP; Shih BB; Brown JA; Cooke AJ; Mackey A; Einson J; Zairis S; Rivas-Delgado A; Laginestra MA; Pileri S; Campo E; Bhagat G; Ferrando AA; Rabadan R; Palomero T
Cell Rep; 2022 Apr; 39(3):110695. PubMed ID: 35443168
[TBL] [Abstract][Full Text] [Related]
4. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.
Wang T; Feldman AL; Wada DA; Lu Y; Polk A; Briski R; Ristow K; Habermann TM; Thomas D; Ziesmer SC; Wellik LE; Lanigan TM; Witzig TE; Pittelkow MR; Bailey NG; Hristov AC; Lim MS; Ansell SM; Wilcox RA
Blood; 2014 May; 123(19):3007-15. PubMed ID: 24497534
[TBL] [Abstract][Full Text] [Related]
5. SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target.
Carty SA; Murga-Zamalloa CA; Wilcox RA
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):561-574. PubMed ID: 37142534
[TBL] [Abstract][Full Text] [Related]
6. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract][Full Text] [Related]
7. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments.
Nakhoul H; Lin Z; Wang X; Roberts C; Dong Y; Flemington E
mSphere; 2019 Jul; 4(4):. PubMed ID: 31292228
[TBL] [Abstract][Full Text] [Related]
9. Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
Le K; Vollenweider J; Han J; Staudinger N; Stenson M; Bayraktar L; Wellik LE; Maurer MJ; McPhail ED; Witzig TE; Gupta M
Hematol Oncol; 2024 Jan; 42(1):e3233. PubMed ID: 37876297
[TBL] [Abstract][Full Text] [Related]
10. The aggressive peripheral T-cell lymphomas: 2013.
Armitage JO
Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
[TBL] [Abstract][Full Text] [Related]
11. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
12. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
Armitage JO
Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features.
Balagué O; Martínez A; Colomo L; Roselló E; Garcia A; Martínez-Bernal M; Palacín A; Fu K; Weisenburger D; Colomer D; Burke JS; Warnke RA; Campo E
Am J Surg Pathol; 2007 Sep; 31(9):1310-22. PubMed ID: 17721185
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y; Li X; Luan Y; Luo J; Dong Q; Ye S; Li Y; Li Y; Jia L; Yang J; Yang DH
Mol Cancer; 2024 Jan; 23(1):2. PubMed ID: 38178117
[TBL] [Abstract][Full Text] [Related]
15. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
Huang D; Song TL; Nairismägi ML; Laurensia Y; Pang WL; Zhe DCM; Wong EKY; Wijaya GG; Tan J; Tan SH; Lim JQ; Chia BKH; Chan JY; Tang TPL; Somasundaram N; Cheng CL; Politz O; Liu N; Lim ST; Ong CK
Br J Haematol; 2020 May; 189(4):731-744. PubMed ID: 32004387
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.
Pedersen MB; Hamilton-Dutoit SJ; Bendix K; Møller MB; Nørgaard P; Johansen P; Ralfkiaer E; Brown Pde N; Hansen PB; Jensen BA; Madsen J; Schöllkopf C; d'Amore F
Hematol Oncol; 2015 Dec; 33(4):120-8. PubMed ID: 25052551
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ; Ghione P; Jacobsen E; Ruan J; Schatz JH; Noor S; Myskowski P; Vardhana S; Ganesan N; Hancock H; Davey T; Perez L; Ryu S; Santarosa A; Dowd J; Obadi O; Pomerantz L; Yi N; Sohail S; Galasso N; Neuman R; Liotta B; Blouin W; Baik J; Geyer MB; Noy A; Straus D; Kumar P; Dogan A; Hollmann T; Drill E; Rademaker J; Schoder H; Inghirami G; Weinstock DM; Horwitz SM
Blood; 2021 Dec; 138(26):2828-2837. PubMed ID: 34653242
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
Bennani NN; Kim HJ; Pederson LD; Atherton PJ; Micallef IN; Thanarajasingam G; Nowakowski GS; Witzig T; Feldman AL; Ansell SM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35750419
[TBL] [Abstract][Full Text] [Related]
20. The aggressive peripheral T-cell lymphomas: 2017.
Armitage JO
Am J Hematol; 2017 Jul; 92(7):706-715. PubMed ID: 28516671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
